In this study, the median PFS2 defined by median survival time from enrollment to progressive disease of second-line treatment was 28.6 months in the A + T group and 24.3 months in the TKI alone group (HR, 0.80; 95% CI, 0.59 to 1.10), which indicated that the additional effect of bevacizumab on erlotinib monotherapy in NSCLC with EGFR mutations gradually decreased [13]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.